Home / Content / B2B Connect / Pharma / US FDA approves Natco Pharma's anti-cancer drug azacitidine

US FDA approves Natco Pharma's anti-cancer drug azacitidine

The approved product is a generic version of Vidaza, which recorded annual sales of $ 188 mn

Premium

Last Updated : Jun 27 2017 | 3:39 PM IST

Natco Pharma Limited has received final approval from the US Food and Drug Administration (FDA) for azacitidine injection used in the treatment of cancer. “Natco Pharma Limited is pleased to announce final approval of abbreviated new drug application (ANDA) from the US FDA for azacitidine for injection, 100 mg per vial, single-dose vial - a generic version of Vidaza by Celgene Corporation,” said the company in a press release.

Natco and its marketing partner Breckenridge Pharmaceutical Inc (BPI) plan to launch this product in the US market in the near future.

Vidaza is a prescription anti-cancer chemotherapy drug that is

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in